Stock analysts at Roth Capital started coverage on shares of Acer Therapeutics (NASDAQ:ACER) in a research report issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $70.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price objective suggests a potential upside of 288.89% from the company’s previous close.
Several other equities research analysts have also recently weighed in on the company. William Blair began coverage on Acer Therapeutics in a research report on Friday, February 16th. They issued an “outperform” rating for the company. HC Wainwright set a $50.00 price objective on Acer Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 4th. Finally, ValuEngine cut Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
Shares of Acer Therapeutics (NASDAQ ACER) opened at $18.00 on Monday. Acer Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63. The firm has a market capitalization of $136.30, a P/E ratio of -4.47 and a beta of 2.58.
About Acer Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.